Intervention

ziprasidone

ClinicalTrials.gov intervention label

Clinical trials17

Recruiting0

Common conditions17

Lead sponsors shown12

Clinical trials

17 shown

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic MedicationNCT03557931 · 2018-07-13

Antipsychotics and Gene Expression in Soft TissuesNCT01185743 · 2010-07-01

Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive DisorderNCT01168674 · 2010-02-01

Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial CapsulesNCT00821444 · 2009-01-01

Ziprasidone vs Standard Therapy for Agitated Patients in the EDNCT00786318 · 2008-09-01

Ziprasidone in the Psychosis ProdromeNCT00635700 · 2008-03-01

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to ZiprasidoneNCT00538642 · 2007-08-01

Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.NCT00454883 · 2007-04-01

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To ZiprasidoneNCT00406315 · 2006-11-01

A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox CapsuleNCT01053429 · 2005-06-01

Efficacy and Tolerability of Switching to Ziprasidone From Other AntipsychoticsNCT00458211 · 2005-05-01

Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective DisorderNCT00137020 · 2004-11-01

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective TrialNCT00224315 · 2003-11-01

Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind StudyNCT00145444 · 2003-03-01

Glucose and Lipid Metabolism on Antipsychotic MedicationNCT00515723 · 2001-09-01

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With SchizophreniaNCT00034801 · 2001-09-01

CATIE- Schizophrenia TrialNCT00014001 · 2000-12-01

Common conditions

Schizophrenia11 Schizoaffective Disorder5 Bipolar Disorder3 Depression2 Psychotic Disorders2 Affective Psychosis, Bipolar1 Agitation1 Delirium1 Diabetes1 Healthy1 Hyperglycemia1 Mania1 Manic-Depressive Psychosis1 Psychosis1 Psychosis Prodrome1 Schizophrenia, Schizoaffective Disorder1 Type 2 Diabetes Mellitus1

Leading sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.6 Astellas Pharma Global Development, Inc.1 Bronx Psychiatric Center1 Central Institute of Mental Health, Mannheim1 Eli Lilly and Company1 George Washington University1 Medical University of Vienna1 National Institute of Mental Health (NIMH)1 The University of Texas Health Science Center at San Antonio1 Tufts Medical Center1 Washington University School of Medicine1 Yale University1

Trial status mix

COMPLETED16

WITHDRAWN1

Phase mix

PHASE49

NA2

PHASE22

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.